Evidence map›Paper›PMID 42192636›Full record

ArticleBMJ open2026

Recombinant human brain natriuretic peptide for the recovery stage of septic shock: an interventional study protocol.

Jing-Chao Luo, Tao Mou, Ma Li, Wen-Tao Feng, Rui-Ming Yue, Chun Pan, Xiao-Bo Huang, Eduardo Kattan, Yi Zhang, Ling-Ai Pan

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06745206 (Recombinant Human Brain Natriuretic Peptide for the Recovery Stage of Septic Shock), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06745206 nanot yet recruitingnot on this map

Recombinant Human Brain Natriuretic Peptide for the Recovery Stage of Septic Shock: An Interventional Pilot Study

TypeinterventionalSponsorSichuan Provincial People's HospitalRan2025 to 2026Enrolled30ConditionsSepsis-induced Cardiomyopathy, the Recovery Phase of Septic ShockArmsLyophilized Recombinant Human Brain Natriuretic Peptide
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jing-Chao LuoDepartment of Critical Care Medicine, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Tao MouDepartment of Critical Care Medicine, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Ma LiMedical Administration Department, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Wen-Tao FengDepartment of Critical Care Medicine, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Rui-Ming YueDepartment of Critical Care Medicine, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Chun PanDepartment of Critical Care Medicine, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.ORCID http://orcid.org/0000-0002-6077-5882
Xiao-Bo HuangDepartment of Critical Care Medicine, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Eduardo KattanDepartamento de Medicina Intensiva, Pontificia Universidad Católica de Chile Facultad de Medicina, Santiago, Chile zhangyi@med.uestc.edu.cn e.kattan@gamil.com panlingai2004@163.com.
Yi ZhangDepartment of Critical Care Medicine, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China zhangyi@med.uestc.edu.cn e.kattan@gamil.com panlingai2004@163.com.ORCID http://orcid.org/0000-0001-7213-0777
Ling-Ai PanDepartment of Critical Care Medicine, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China zhangyi@med.uestc.edu.cn e.kattan@gamil.com panlingai2004@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIn the de-resuscitation phase of septic shock, resolving vasoplegia and fluid mobilisation can increase venous congestion in patients with sepsis-related myocardial dysfunction. This study will characterise the haemodynamic effects and safety of recombinant human brain natriuretic peptide (rh-BNP) in this population. METHODS AND ANALYSIS: This single-centre, prospective, single-arm study will enrol 30 adults recovering from septic shock with improving infection/vasopressor trends, sinus rhythm, ongoing pulse-index continuous cardiac output (PiCCO) monitoring and measurable arm-equilibrium pressure (Parm). Eligibility will require cardiac dysfunction (left-ventricular ejection fraction ≤50% and/or ≥10% absolute decline when available) and volume overload (global end-diastolic volume index >800 mL/m² and extravascular lung water index >10 mL/kg). Participants will receive rh-BNP (2 µg/kg intravenous bolus over 15 min, then a 0.01 µg/kg/min infusion for up to 72 hours). Measurements will be obtained at baseline, acute response (30-60 min), 24, 48 and 72 hours. The primary outcome will be within-patient change in venous return pressure gradient (ΔPVR, Parm-central venous pressure) from baseline to acute response. Secondary outcomes will include indices of preload, cardiac function, tissue perfusion and venous congestion. Haemodynamic instability will be the safety endpoint. Paired tests and repeated-measures analyses will estimate within-patient changes over time. ETHICS AND DISSEMINATION: Ethics approval has been obtained from the Ethics Committee of Sichuan Provincial People's Hospital, Sichuan Academy of Medical Sciences (No. 2024-653-1). Written informed consent will be obtained. Findings will be disseminated via peer-reviewed publications and conferences. TRIAL REGISTRATION NUMBER: NCT06745206.

Indexed as

Natriuretic Peptide, BrainShock, SepticAdultClinical Trials as TopicFemaleHemodynamicsHumansMaleMiddle AgedProspective StudiesRecombinant ProteinsNatriuretic Peptide, BrainRecombinant ProteinsAdult intensive & critical careIntensive Care UnitsINTENSIVE & CRITICAL CARESepsis

Identifiers

PMID42192636
PMCPMC13202010

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.